{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:00:13Z","timestamp":1790852413358,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.acra.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:29:18Z","timestamp":1785209358000},"page":"4606-4618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0006-9089","authenticated-orcid":false,"given":"Motohiko","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-6981","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kushiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yanagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.acra.2026.07.007_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.acra.2026.07.007_bib2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.acra.2026.07.007_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.acra.2026.07.007_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.acra.2026.07.007_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.acra.2026.07.007_bib6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.acra.2026.07.007_bib7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.acra.2026.07.007_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.acra.2026.07.007_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.07.007_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.acra.2026.07.007_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/biomedicines10040790","article-title":"Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC): their incidence, management, multiorgan irAEs, and rechallenge","volume":"10","author":"Vaddepally","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.acra.2026.07.007_bib12","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.chest.2021.12.656","article-title":"Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis","volume":"161","author":"Zhang","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.acra.2026.07.007_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non\u2013small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.acra.2026.07.007_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.acra.2024.08.043","article-title":"18F-FDG-PET\/CT uptake by noncancerous lung as a predictor of interstitial lung disease induced by immune checkpoint inhibitors","volume":"32","author":"Yamazaki","year":"2025","journal-title":"Acad Radiol"},{"key":"10.1016\/j.acra.2026.07.007_bib15","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. Department of Health and Human Services; 2017. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"issue":"5","key":"10.1016\/j.acra.2026.07.007_bib16","article-title":"TotalSegmentator: robust segmentation of 104 anatomical structures in CT images","volume":"5","author":"Wasserthal","year":"2023","journal-title":"Radiol\u00a0Artif Intell"},{"issue":"9","key":"10.1016\/j.acra.2026.07.007_bib17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.acra.2026.07.007_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","article-title":"Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis","volume":"2","author":"Larson","year":"1999","journal-title":"Clin Positron Imaging"},{"issue":"9","key":"10.1016\/j.acra.2026.07.007_bib19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.2967\/jnumed.112.116921","article-title":"18F-FDG PET early response evaluation of locally advanced NSCLC treated with concomitant chemoradiotherapy","volume":"54","author":"Usmanij","year":"2013","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.acra.2026.07.007_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMoa1007285","article-title":"Lung volumes and emphysema in smokers with interstitial lung abnormalities","volume":"364","author":"Washko","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acra.2026.07.007_bib21","series-title":"IBM SPSS Statistics for Windows, Version 25.0","author":"IBM Corp","year":"2017"},{"key":"10.1016\/j.acra.2026.07.007_bib22","series-title":"R: A language and environment for statistical computing","author":"Core Team","year":"2021"},{"key":"10.1016\/j.acra.2026.07.007_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.03.016","article-title":"Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-na\u00efve patients with non-squamous non-small cell lung cancer: a\u00a0multicentre, retrospective cohort study","volume":"150","author":"Fujimoto","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acra.2026.07.007_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1402017","article-title":"Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Ma","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.acra.2026.07.007_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.acra.2026.07.007_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.acra.2026.07.007_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor responses","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"2","key":"10.1016\/j.acra.2026.07.007_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00259-013-2514-8","article-title":"Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients","volume":"41","author":"Win","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.acra.2026.07.007_bib29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2967\/jnumed.116.174946","article-title":"18F-FDG uptake in less affected lung field provides prognostic stratification in patients with interstitial lung disease","volume":"57","author":"Nobashi","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.acra.2026.07.007_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12890-021-01659-4","article-title":"18F-FDG PET\/CT predicts acute exacerbation in idiopathic pulmonary fibrosis after thoracic surgery","volume":"21","author":"Yoon","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.acra.2026.07.007_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12890-024-03177-5","article-title":"Predictors for acute exacerbation of interstitial pneumonia following lung cancer surgery: a multicenter study","volume":"24","author":"Yin","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.acra.2026.07.007_bib32","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00262-023-03408-4","article-title":"Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study","volume":"72","author":"Fujimoto","year":"2023","journal-title":"Cancer Immunol Immunother"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226005167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226005167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:49:45Z","timestamp":1790851785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633226005167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1076633226005167"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2026.07.007","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Association of Academic Radiology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}